Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
about
Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-AnalysisMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationVenous and arterial thrombotic risks with thalidomide: evidence and practical guidanceOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practiceOlder patients with myeloma derive similar benefit from autologous transplantation.Time-dependent endpoints as predictors of overall survival in multiple myelomaAge and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Review of health-related quality of life data in multiple myeloma patients treated with novel agents.Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer.Multiple myeloma in the older adult: better prospects, more challenges.Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.IMWG consensus on maintenance therapy in multiple myeloma.Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.European perspective on multiple myeloma treatment strategies: update following recent congressesThe cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maiThe rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution.Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.Senior adult oncology.Challenges in multiple myeloma diagnosis and treatment.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyLong-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.Treatment of multiple myeloma in the elderly: realities and hopes.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Treatment of newly diagnosed myeloma in patients not eligible for transplantation.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveManaging multiple myeloma in the elderly: are we making progress?Bortezomib for previously untreated multiple myeloma.
P2860
Q26767418-D009C311-98DA-4D9B-9556-92C4A9901476Q26998884-C8B08713-CE02-4032-BAA4-7A68658896EDQ27002668-0C46338B-1AB1-4FC5-9B3A-CD802FF7CAD0Q27008491-3F5E1708-0898-4E15-8D76-BA1C04C83CFBQ28077567-EB54B0F7-96CB-4118-A9A2-673C2BE70D27Q30370038-7AFF4D05-5EDA-4642-ADB0-68A4555474F1Q30538040-481A0578-4933-474D-863F-6903B75AA558Q30595175-AC5484F3-B7D8-418C-BD29-861FFF1FC7F5Q30650394-5A103EC1-B459-44A5-8122-48E3B5B8F4E3Q33564241-D1C64F9C-6C49-4C82-9C1C-60422892B056Q34031129-225B1B3B-AE04-4175-B15F-2643EB2348E7Q34038959-F754C783-DCA8-4AA6-ADDE-8959D5620772Q34253548-6FD8BF1B-09E7-4C0F-BCE3-0C05E3AEB61EQ34372086-A0B3FD73-4621-4857-AFA7-443B7024CDABQ35153760-6EE863C5-C3B5-442C-BA7D-B350F3337B9CQ35631904-8BCDC510-1E82-43EF-AB1E-BEAC5FBA16DFQ35669893-1A29F102-8F8D-41FF-8A5D-2889290E6447Q35876966-7CB765F7-7403-4572-991E-F6C87C8C4A2DQ35932505-7BC57924-7ACA-4477-9A88-1F10EA562542Q35989943-95A289C4-5BF3-465D-A7D3-E72514871E3EQ36565628-BDC3EFE0-BCF2-43BD-83DE-2AEFD67DF8F8Q36612613-58414FA3-03DE-4F85-94E8-AD13D7297037Q36654092-57BD2E83-8F0A-4C8B-BCA9-12FB52E48B85Q36706899-3746E98F-A7D5-42A8-BE68-E08D8CB1475AQ36777233-E6B3B28B-5D1E-4889-901A-92DD5E1A3B05Q36851424-A51FD89D-DAB7-4A36-83DD-67306A74ECEAQ36852225-C5B2EFC4-159F-4B8F-B50C-06C4B474C855Q36963203-0563F3F8-3273-460F-9F21-4762A8AE8B73Q37228026-F6AB9246-3BC4-4314-BCAA-18594F50BC90Q37536148-4A116D47-79A7-46F4-8E7D-AE24D25F98B3Q37623809-CF23B347-64A5-481A-8BDE-7B6501739DBDQ37724272-97776CE7-D490-4EC8-81AB-9B288AA8A5E9Q37809535-D4BAFF6A-88C4-4265-99C3-B7EFC70014DBQ37842346-A9AC20F0-5C13-4CBD-95D3-0D401B2B48CBQ37846567-5BACF0D5-6B6F-463F-BA4B-BE3B41D5E123Q37851944-8C1DD660-40CD-4179-8866-0C1AC74FF887Q37857784-D102B786-4E10-4DBB-97CA-BE7A3BFE66C5Q37858327-536D2D2E-ECD3-427C-946E-C6405083873CQ37888716-C2EACC6B-E680-41AF-A3B0-5243024A92F8Q37937699-9D9E925E-74BE-49FC-B3F1-3B8ADF174D13
P2860
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Phase III study of the value o ...... e myeloma: the HOVON 49 Study.
@en
Phase III study of the value o ...... e myeloma: the HOVON 49 Study.
@nl
type
label
Phase III study of the value o ...... e myeloma: the HOVON 49 Study.
@en
Phase III study of the value o ...... e myeloma: the HOVON 49 Study.
@nl
prefLabel
Phase III study of the value o ...... e myeloma: the HOVON 49 Study.
@en
Phase III study of the value o ...... e myeloma: the HOVON 49 Study.
@nl
P2093
P356
P1476
Phase III study of the value o ...... e myeloma: the HOVON 49 Study.
@en
P2093
Dutch-Belgium Cooperative Group HOVON
Fabian Termorshuizen
Harm Sinnige
Henk Lokhorst
Marinus van Marwijk Kooy
Martijn Schaafsma
Pierre Wijermans
René van der Griend
Rianne Ammerlaan
Shulamiet Wittebol
P304
P356
10.1200/JCO.2009.26.1610
P407
P577
2010-06-01T00:00:00Z